Fundraising Fox

Novus Therapeutics

NASDAQ: ELDN

Irvine, US · Delaware corporation

Biotech

Founders & leadership

JK
Jon KuwaharaExecutive
GF
Gregory FlesherExecutive
CC
Cheryl CohenNamed on SEC filing
KK
Keith KatkinNamed on SEC filing
JM
John McBrideNamed on SEC filing
GL
Gary LyonsNamed on SEC filing
CT
Catherine TurkelNamed on SEC filing

Board

EC
Erez ChimovitsBoard director

Reported raises · per SEC filings

Form D private placements

$194.9M disclosed across 5 rounds · 2019–2024

▶$50MraisedMay 2024 · 24 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Steven PerrinExecutive Officer, Director
  • David-Alexandre GrosExecutive Officer, Director
  • June LeeDirector
  • Allan KirkDirector
  • John McBrideDirector
  • James RobinsonDirector
  • Keith KatkinDirector
  • Jan HillsonDirector
  • Paul LittleExecutive Officer
  • Bryan SmithExecutive Officer
  • Walter OgierDirector
Amount sold
$50M
Sales commissions
$1.6M
Placement agents
Leerink Partners LLC, Noble Capital Markets, Inc.
First sale
May 2024
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$35MraisedMay 2023 · 38 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Jan HillsonDirector
  • John McBrideDirector
  • Bryan SmithExecutive Officer
  • Keith KatkinDirector
  • Walter OgierDirector
  • Gary LyonsDirector
  • Steven PerrinExecutive Officer, Director
  • Paul LittleExecutive Officer
  • June LeeDirector
  • David-Alexandre GrosExecutive Officer, Director
Amount sold
$35M
Sales commissions
$1.2M
Placement agents
Noble Capital Markets, Inc., SVB Securities LLC
First sale
May 2023
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$108.1MraisedSep 2020 · 35 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • John McBrideDirector
  • David-Alexandre GrosExecutive Officer, Director
  • Steven N. PerrinDirector
  • Gary LyonsDirector
  • Jon KuwaharaExecutive Officer
  • Keith A. KatkinDirector
  • Walter OgierDirector
Offering amount
$108.1M
Amount sold
$108.1M
Minimum investment
$498
Sales commissions
$4.1M
Placement agents
Noble Capital Markets, Inc., SVB Leerink LLC
First sale
Sep 2020
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$862.3KraisedJan 2020 · 10 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Keith KatkinDirector
  • Gregory FlesherExecutive Officer, Director
  • Erez ChimovitsDirector
  • Cheryl CohenDirector
  • Jon KuwaharaExecutive Officer
  • John McBrideDirector
  • Gary LyonsDirector
  • Catherine TurkelExecutive Officer
Offering amount
$5.8M
Amount sold
$862.3K
Sales commissions
$60.4K
Placement agents
H.C. Wainwright & Co., LLC
First sale
Jan 2020
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$862.3KraisedMay 2019 · 10 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Jon KuwaharaExecutive Officer
  • Gregory FlesherExecutive Officer, Director
  • Erez ChimovitsDirector
  • Cheryl CohenDirector
  • Keith KatkinDirector
  • John McBrideDirector
  • Gary LyonsDirector
  • Catherine TurkelExecutive Officer
Offering amount
$28.5M
Amount sold
$862.3K
Sales commissions
$60.4K
Placement agents
H.C. Wainwright and Co., LLC
First sale
May 2019
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Frequently asked questions

How much funding has Novus Therapeutics raised?
Novus Therapeutics has disclosed $194.9M raised across 5 rounds.
Where is Novus Therapeutics headquartered?
Novus Therapeutics is headquartered in Irvine, US.